Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148


Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu RI, Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2019 Mar 22. pii: blood-2018-09-874578. doi: 10.1182/blood-2018-09-874578. [Epub ahead of print]


Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Toppaldoddi KR, da Costa Cacemiro M, Bluteau O, Panneau-Schmaltz B, Pioch A, Muller D, Villeval JL, Raslova H, Constantinescu SN, Plo I, Vainchenker W, Marty C.

Oncogene. 2019 Mar;38(10):1651-1660. doi: 10.1038/s41388-018-0538-z. Epub 2018 Oct 19.


Influence of the familial Alzheimer's disease-associated T43I mutation on the transmembrane structure and γ-secretase processing of the C99 peptide.

Tang TC, Kienlen-Campard P, Hu Y, Perrin F, Opsomer R, Octave JN, Constantinescu SN, Smith SO.

J Biol Chem. 2019 Apr 12;294(15):5854-5866. doi: 10.1074/jbc.RA118.006061. Epub 2019 Feb 12.


Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

Leroy E, Balligand T, Pecquet C, Mouton C, Colau D, Shiau AK, Dusa A, Constantinescu SN.

J Allergy Clin Immunol. 2019 Jan 29. pii: S0091-6749(19)30115-0. doi: 10.1016/j.jaci.2018.12.1023. [Epub ahead of print]


The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters.

Defour JP, Levy G, Leroy E, Smith SO, Constantinescu SN.

Leukemia. 2019 Feb;33(2):563-564. doi: 10.1038/s41375-018-0356-x. Epub 2019 Jan 11. No abstract available.


Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.

Mambet C, Babosova O, Defour JP, Leroy E, Necula L, Stanca O, Tatic A, Berbec N, Coriu D, Belickova M, Kralova B, Lanikova L, Vesela J, Pecquet C, Saussoy P, Havelange V, Diaconu CC, Divoky V, Constantinescu SN.

Blood. 2018 Dec 20;132(25):2695-2699. doi: 10.1182/blood-2018-04-843060. Epub 2018 Oct 30. No abstract available.


Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.

Ngo A, Koay A, Pecquet C, Diaconu CC, Jenkins DA, Shiau AK, Constantinescu SN, Choong ML.

Methods Mol Biol. 2018;1787:53-66. doi: 10.1007/978-1-4939-7847-2_4.


Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.

Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. Review.


Thrombopoietin protects hematopoietic stem cells from retrotransposon-mediated damage by promoting an antiviral response.

Barbieri D, Elvira-Matelot E, Pelinski Y, Genève L, de Laval B, Yogarajah G, Pecquet C, Constantinescu SN, Porteu F.

J Exp Med. 2018 May 7;215(5):1463-1480. doi: 10.1084/jem.20170997. Epub 2018 Apr 3.


JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN.

F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018. Review.


New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.

Pasquier F, Marty C, Balligand T, Verdier F, Grosjean S, Gryshkova V, Raslova H, Constantinescu SN, Casadevall N, Vainchenker W, Bellanné-Chantelot C, Plo I.

Haematologica. 2018 Apr;103(4):575-586. doi: 10.3324/haematol.2017.176370. Epub 2017 Dec 21.


β-Sheet Structure within the Extracellular Domain of C99 Regulates Amyloidogenic Processing.

Hu Y, Kienlen-Campard P, Tang TC, Perrin F, Opsomer R, Decock M, Pan X, Octave JN, Constantinescu SN, Smith SO.

Sci Rep. 2017 Dec 7;7(1):17159. doi: 10.1038/s41598-017-17144-0.


Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.

Leroy E, Constantinescu SN.

Leukemia. 2017 Dec;31(12):2853. doi: 10.1038/leu.2017.158.


Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.


An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Defour JP, Hoade Y, Reuther AM, Callaway A, Ward D, Chen F, Constantinescu SN, Cross NCP.

Leukemia. 2017 Aug;31(8):1838-1839. doi: 10.1038/leu.2017.153. Epub 2017 May 22. No abstract available.


The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.

Varghese LN, Defour JP, Pecquet C, Constantinescu SN.

Front Endocrinol (Lausanne). 2017 Mar 31;8:59. doi: 10.3389/fendo.2017.00059. eCollection 2017. Review.


Journal of Cellular and Molecular Medicine: the Future.

Constantinescu SN.

J Cell Mol Med. 2017 Feb;21(2):206-207. doi: 10.1111/jcmm.13075. No abstract available.


Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.

Leroy E, Constantinescu SN.

Leukemia. 2017 May;31(5):1023-1038. doi: 10.1038/leu.2017.43. Epub 2017 Jan 25. Review. Erratum in: Leukemia. 2017 Dec;31(12 ):2853.


An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.

Favale F, Messaoudi K, Varghese LN, Boukour S, Pecquet C, Gryshkova V, Defour JP, Albu RI, Bluteau O, Ballerini P, Leverger G, Plo I, Debili N, Raslova H, Favier R, Constantinescu SN, Vainchenker W.

Blood. 2016 Dec 29;128(26):3146-3158. doi: 10.1182/blood-2016-06-722058. Epub 2016 Nov 10.


A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.

Ngo A, Koay AZ, Pecquet C, Diaconu CC, Ould-Amer Y, Huang Q, Kang C, Poulsen A, Lee MA, Jenkins D, Shiau A, Constantinescu SN, Choong ML.

Comb Chem High Throughput Screen. 2016;19(10):824-833. doi: 10.2174/1386207319666161010163825.


Supplemental Content

Loading ...
Support Center